Pharmacokinetics of Dabigatran Etexilate (Pradaxa®) During Haemodialysis

Inclusion criteria: * End stage renally disease (ESRD), undergoing haemodialysis * ESRD patients in relatively good health * Age 21 - 60 years inclusive * Signed and dated written informed consent prior to admission to the study Exclusion criteria: * Clinically relevant laboratory or physical examination abnormalities (except for renal function tests or deviation of clinical laboratory values) that are related to renal impairment * Moderate and severe concurrent liver function impairment * Surgery of gastrointestinal tract (except appendectomy or herniotomy) or evidence of significant gastrointestinal motility problems * Recent or contemplated diagnostic or therapeutic procedures with potential for uncontrollable bleeding * Intake of medication, which influences the blood clotting * Subjects not able to understand and comply with protocol requirements, instructions and protocol-stated restrictions * For women with childbearing potential: no reliable contraception * Participation in another trial with an investigational drug (\<2 months prior to administration or during trial) * Scheduled to receive a donor kidney transplant during the course of the study